As of September 30, 2022, Clearside’s cash and cash equivalents totaled $53.4 million. The Company believes this cash balance will provide financial runway into 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLSD:
- Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
- Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
- Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
- Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022